

Drug Monograph

Drug/Drug **Arnuity Ellipta™ (fluticasone furoate) inhaler /Inhaled**
 Class: **Corticosteroid**
 Prepared for: MO HealthNet
 Prepared by: Xerox Heritage, LLC

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.	
Dosage Forms:	Arnuity Ellipta™ is available as a 100 mcg inhaler containing a foil strip with 30 blisters or 14 blisters and a 200 mcg inhaler containing a foil strip with 30 blisters or 14 blisters.	
Manufacturer:	GlaxoSmithKline, Research Triangle Park, NC 27709	
Indications:	Arnuity Ellipta™ is indicated for the once-daily maintenance treatment of asthma as prophylactic therapy in patients aged 12 years and older.	
Costs:	\$130.20 per 100 mcg inhaler and \$174.30 per 200 mcg inhaler of Arnuity Ellipta™. Wholesale Acquisition Cost	
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List and is a non-preferred agent.	
Status Recommendation:	<input type="checkbox"/> Prior Authorization (PA) Required	<input type="checkbox"/> Open Access
	<input type="checkbox"/> Fiscal Edit	<input checked="" type="checkbox"/> PDL
Type of PA Criteria:	<input type="checkbox"/> Increased Risk of ADE	<input checked="" type="checkbox"/> Non-Preferred Agent
	<input type="checkbox"/> Appropriate Indications	<input type="checkbox"/> Under Solicitation

Prepared By: Luke Boehmer Pharm.D.
 Date: March 9, 2015